Abstract:Anti-bacterial monoclonal antibody (mAb) therapies either rely on toxin neutralization or opsonophagocytic killing (OPK). Toxin neutralization protects the host from toxin-induced damage, while leaving the organism intact. OPK inducing antibodies clear the bacteria but leave the released toxins unencountered. Infection site targeted anti-toxin antibodies (ISTAbs) that we report here addresses this binary paradigm by combining both functionalities into a single molecule. ISTAbs consist of cell wall targeting (CWT) domains of bacteriophage endolysins fused to toxin neutralizing mAbs (IgG). CWT governs specific binding to the surface of bacteria while the IgG variable domain neutralizes the toxins as they are released. The complex is then cleared by phagocytic cells. As proof of concept, we generated several ISTAb prototypes targeting major toxins from two Gram-positive spore forming pathogens that have a high clinical significance; Clostridium difficile, causative agent of the most common hospital-acquired infection, and Bacillus anthracis, a Category A select agent pathogen. Both groups of ISTAbs exhibited potent toxin neutralization, binding to their respective bacterial cells, and induction of opsonophagocytosis. In mice infected with B. anthracis, ISTAbs exhibit significantly higher efficacy than parental IgG in both pre- and post-challenge models. Furthermore, ISTAbs fully protected against B. anthracis infection in a nonhuman primate (NHP) aerosol challenge model. These findings establish that as a platform technology, ISTAbs are broadly applicable for therapeutic intervention against several toxigenic bacterial pathogens.

Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications

Toxins and Derivatives in Molecular Pharmaceutics: Drug Delivery and Targeted Therapy.

An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies

A potential delivery system based on cholera toxin: A macromolecule carrier with multiple activities

Novel approaches for bacterial toxin neutralization; current advances and future perspectives.

Engineered antibodies targeted to bacterial surface integrate effector functions with toxin neutralization to provide superior efficacy against bacterial infections

Some Examples of Bacterial Toxins as Tools

Pharmacological Targeting of Pore-Forming Toxins as Adjunctive Therapy for Invasive Bacterial Infection

Microbial carbohydrate-binding toxins - From etiology to biotechnological application

In Situ Capture of Bacterial Toxins for Antivirulence Vaccination

Advances in the Study of Bacterial Toxins, Their Roles and Mechanisms in Pathogenesis

Structural and Functional Insights into the Delivery Systems of Bacillus and Clostridial Binary Toxins

Enhanced delivery of protein therapeutics with a diphtheria toxin-like platform that evades pre-existing neutralizing immunity

Discovery of novel bacterial toxins by genomics and computational biology

A Journey of Cytolethal Distending Toxins through Cell Membranes

Host Tropism and Structural Biology of ABC Toxin Complexes

Prospects for the use of viral proteins for the construction of chimeric toxins

Cell-Free Synthesis of Protein Toxins for Medical and Diagnostic Applications

Recombinant Derivatives of Clostridial Neurotoxins as Delivery Vehicles for Proteins and Small Organic Molecules

Exploring the Toxin-Mediated Mechanisms in Clostridioides difficile Infection

A Novel Strategy to Target Lethal Peptides Against Antibiotic Resistant Bacteria.